1. Home
  2. ELVN vs HOV Comparison

ELVN vs HOV Comparison

Compare ELVN & HOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • HOV
  • Stock Information
  • Founded
  • ELVN 2016
  • HOV 1959
  • Country
  • ELVN United States
  • HOV United States
  • Employees
  • ELVN N/A
  • HOV N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • HOV Homebuilding
  • Sector
  • ELVN Health Care
  • HOV Consumer Discretionary
  • Exchange
  • ELVN Nasdaq
  • HOV Nasdaq
  • Market Cap
  • ELVN 1.3B
  • HOV 1.3B
  • IPO Year
  • ELVN 2020
  • HOV N/A
  • Fundamental
  • Price
  • ELVN $25.91
  • HOV $181.33
  • Analyst Decision
  • ELVN Strong Buy
  • HOV Hold
  • Analyst Count
  • ELVN 4
  • HOV 1
  • Target Price
  • ELVN $36.75
  • HOV $155.00
  • AVG Volume (30 Days)
  • ELVN 244.8K
  • HOV 63.6K
  • Earning Date
  • ELVN 11-13-2024
  • HOV 12-03-2024
  • Dividend Yield
  • ELVN N/A
  • HOV N/A
  • EPS Growth
  • ELVN N/A
  • HOV 48.22
  • EPS
  • ELVN N/A
  • HOV 31.75
  • Revenue
  • ELVN N/A
  • HOV $2,912,312,000.00
  • Revenue This Year
  • ELVN N/A
  • HOV N/A
  • Revenue Next Year
  • ELVN N/A
  • HOV N/A
  • P/E Ratio
  • ELVN N/A
  • HOV $5.42
  • Revenue Growth
  • ELVN N/A
  • HOV 5.68
  • 52 Week Low
  • ELVN $9.80
  • HOV $86.61
  • 52 Week High
  • ELVN $30.03
  • HOV $240.34
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 41.12
  • HOV 45.81
  • Support Level
  • ELVN $24.69
  • HOV $164.70
  • Resistance Level
  • ELVN $26.48
  • HOV $188.60
  • Average True Range (ATR)
  • ELVN 1.38
  • HOV 8.94
  • MACD
  • ELVN -0.32
  • HOV 0.39
  • Stochastic Oscillator
  • ELVN 28.35
  • HOV 42.21

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About HOV Hovnanian Enterprises Inc.

Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.

Share on Social Networks: